Liposomes capable of effectively binding the beta amyloid peptide
AssigneeUniversita degli Studi de Milano-Bicocca
InventorsMassimo Masserini, Francesca Re, Maria Silvia Sesana
Life of this patent
Estimating the term…
Abstract
Novel liposomes are described which are capable of effectively binding beta amyloid peptide and are useful for the treatment, prevention and diagnosis of Alzheimer's disease. Binding ability is provided by the presence in the formulation of particular natural lipids identified by the Applicant. These comprise a constant component, made up of cholesterol and sphingomyelin, and an additional variable component, made up of selected lipids.
Claims12
A method of reducing Aβ peptide in a patient affected by Alzheimer's disease, characterized by administering to said patient by injection and/or infusion of an amount of liposomes sufficient to reduce Aβ peptide in said patient, wherein the liposomes comprise cholesterol and sphyngomyelin in a 1:1 molar ratio, and one or more additional lipids selected from among cardiolipin and/or L-β,γ-dimyristoyl phosphatidic acid, and wherein the additional lipid accounts for a molar percentage of from 5 to 20%, relative to the total content of cholesterol, sphingomyelin and additional lipid.
A method of reducing Aβ peptide in a patient affected by an overproduction of Aβ peptide, characterized by systemically administering to said patient by injection and/or infusion of an amount of liposomes sufficient to reduce Aβ peptide in said patient, wherein the liposomes comprise cholesterol and sphyngomyelin in a 1:1 molar ratio, and one or more additional lipids selected from among cardiolipin and/or L-β,γ-dimyristoyl phosphatidic acid, and wherein the additional lipid accounts for a molar percentage of from 5 to 20%, relative to the total content of cholesterol, sphingomyelin and additional lipid.
Dependencies are inferred from the claim text.